why is there a semaglutide shortage An Ongoing Crisis: Raises Dual Concerns for Obesity and Diabetes Treatment The FDA recently removed semaglutide

Clinical trial data and post-marketing surveillance suggest that gastrointestinal side effectswhich may contribute to dizzinessare most pronounced during the initial titration phase and tend to diminish as treatment continues

In part 1 Ill look at the initial claims and the people making them, in part 2 Ill do a deeper analysis of the study

Presented for research literature review only Krasowska D et al

The authors are fully responsible for the content and conclusions of the publication

when it occurs, it typically results from improved glucose control, increased fluid intake, or co-prescribed medications rather than the GLP-1 drug itself